Form 8-K - Current report:
SEC Accession No. 0001193125-23-067701
Filing Date
2023-03-10
Accepted
2023-03-10 16:53:01
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d483171d8k.htm   iXBRL 8-K 21337
  Complete submission text file 0001193125-23-067701.txt   141936

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20230310.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20230310_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20230310_pre.xml EX-101.PRE 11261
6 EXTRACTED XBRL INSTANCE DOCUMENT d483171d8k_htm.xml XML 3356
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 23724438
SIC: 2834 Pharmaceutical Preparations